Commitment and experience for changing times

More than any other technology, biotechnology has the potential to alter our lives in a positive way. And by achieving this potential, today’s biotech companies are delivering new levels of health, prosperity and sustainability — across the world. But with increasing regulation, growing pricing pressures and competition for acquisitions, you face unprecedented challenges.

Ernst & Young has been a pioneering presence in the biotechnology industry we were the first professional services firm to build a practice dedicated to serving your industry. We’ve stayed committed to your business with our leading reports and our knowledgeable professionals. So it’s not surprising that we serve more biotech companies than any other professional services firm — by a wide margin.

The Ernst & Young Global Biotechnology Center reflects our continuing commitment to biotechnology. It develops our thought leadership and brings you clear insights to address your assurance, tax, transaction and advisory needs. And it networks and educates our biotech professionals from around the world, so they are informed about the emerging issues impacting your business.

The bottom line? You receive a consistent, high-quality, seamless service — wherever you operate — and the help you need to meet your goals.

Beyond Borders 2007

The 21st annual "Beyond Borders: Ernst & Young's Global Biotechnology Report 2007" looks past the numbers and analyzes the global and regional political, economic and cultural motivators that shaped 2006. Key industry players and advisors share their insights on how they are dealing with the challenges of success.

Financial statement disclosures

Anyone preparing financial statements for biotech and related entities may find this compilation of disclosures and footnotes useful. Taken from the filings of US biotech companies, “Disclosures in biotech” (pdf, 658 kb), from Ernst & Young US, covers specific issues such as revenue recognition and sales allowances, pre-launch inventory, in-process research and development, and research and collaboration arrangements.

Taking drug safety beyond compliance

To keep a company fiscally fit while addressing the complex and often litigious issue of product safety, manufacturers need an integrated approach to managing risks. "Progressions 2007: the Ernst & Young global pharmaceuticals report" explores how companies can implement an enterprise-wide risk function, and covers specific regulatory drivers such as the European Union's initiative regarding Risk Management Plans, planning for drug recalls, and M&A due diligence.

Interpreting the emerging health policy agenda: webcast archive

The US Congressional agenda and its impact on biotechnology and pharmaceutical companies was the subject of the Ernst & Young Thought Center Webcast “A prescription for change” on 6 March 2007. If you missed the live webcast, visit our US site to watch the archived program in video format, where panelists discuss the hot issues around the emerging health policy agenda.

Assessing biotech communications compliance

Regulatory compliance risks stemming from sales and marketing is a challenge many executives and departments share. The pressure is higher now, as more products hit the market. Read this bio*link for suggestions on how companies might monitor potential communications compliance breakdowns (pdf, 101kb) and for questions they can ask to begin establishing a compliance framework.

Strategic business risk – biotechnology 2008

What strategic challenges (pdf, 496kb) are likely to affect biotech companies in 2008? We analyze 10 of the most critical risks, including pricing pressures and access, product development and clinical trials, raising capital and strategic alliances. We also look at risks currently ‘below the radar’ that may be topping risk tables in the years to come.